|
|
|
|
M.Muralidharan Nair |
| Name |
: |
M.Muralidharan Nair |
 |
| Designation |
: |
Partner |
| Organisation |
: |
Ernst and Young |
| |
|
|
| |
|
|
Brief Profile
|
|
Muralidharan Nair is a Partner with the Business Advisory Services practice of EY
(previously known as Ernst & Young) India. He currently leads the Healthcare and
Lifescience practices in advisory.
Murali has a professional career of 21 years behind him, of which for the last 14 years
he has been associated with EY. During this period, he has led and performed advisory
solutions spanning strategy, strategic cost management, business process reengineering,
supply chain effectiveness, finance transformation, performance management and
governance solutions across a gamut of sectors including provider care, pharmaceuticals,
CROs, petrochemicals, agrochemicals, FMCG, retail with a larger focus on the life sciences
sector.
He has also been an adviser to Government of India in his role as the leader of a
commissioned study to recommend on FDI policy in pharmaceutical sector and also policy
initiatives to foster innovation and accelerate exports growth in pharmaceuticals.
Key clients that he has served include Pfizer, AstraZeneca, Baxter, Philips Medical,
Johnson & Johnson; Rallis India, Fortis Hospitals, Max Healthcare, Healthcare Global,
Global Hospitals, Care Hospitals as well as several PE firms with interest in Lifescience and
Healthcare sector.
In addition, he has led thought leadership initiatives in collaboration with industry bodies
such as FICCI, OPPI etc and has authored several publications covering wide range of
subjects including framework for financing and implementing Universal Health Cover,
Effective Reimbursement Model for Healthcare PPP in Inida, health challenges from
nutritional deficiency and role of Nutarceuticals in Inidan context and building an effective
eco system for clinical trials in India.
Murali served on the Advisory Board of Pfizer India. He has also been associated with
healthcare and pharma industry bodies in their representations to the government in regard
to regulatory reforms. He was a member of the National Task Force for Public Private
Partnership in healthcare and an executive member of the FICCI National Healthcare
Committee.
Prior to joining Ernst & Young, Murali has worked with Aventis Pharma for 7 years in
various techno-commercial functions.
|
|
|
|
|
